GreenLight Biosciences Holdings PBC (GRNA) Stock Analyst Ratings

USA • Nasdaq • NASDAQ:GRNA • US39536G1058

0.2995 USD
0 (-0.03%)
At close: Jul 21, 2023
0.2995 USD
0 (0%)
After Hours: 7/21/2023, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Buy % Consensus

46

ChartMill assigns a Buy % Consensus number of 46% to GRNA. The Buy consensus is the weighted average rating of the current analysts ratings.

  • Analysts have set a mean price target forecast of 0.46. This target is 53.26% above the current price.
  • GRNA was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about GRNA.
  • In the previous month the buy percentage consensus was at a similar level.
  • GRNA was analyzed by 7 analysts. More opinions would make the average more meaningful.

Related screens

Find peers with buy consensus above 85%
GRNA Historical Analyst RatingsGRNA Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -8 -7 -6 -5 -4 -3 -2 -1 0 2 4 6

Price Target & Forecast

Price Low Median Mean High 0.300.300.460.460.63 - 1.17% 53.26% 53.26% 110.35%

Related screens

Find peers 30% below price target
GRNA Current Analyst RatingGRNA Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0
Up and Down Grades
Date Firm Action Rating
2023-05-31 Canaccord Genuity Downgrade Buy -> Hold
2022-12-08 Canaccord Genuity Initiate Buy
2022-10-14 Credit Suisse Initiate Outperform

GreenLight Biosciences Holdings PBC / GRNA FAQ

What is the average price target for GreenLight Biosciences Holdings PBC (GRNA) stock?

7 analysts have analysed GRNA and the average price target is 0.46 USD. This implies a price increase of 53.26% is expected in the next year compared to the current price of 0.2995.


What is the consensus rating for GRNA stock?

The consensus rating for GreenLight Biosciences Holdings PBC (GRNA) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.